| DB00001 | Lepirudin | For the treatment of heparin-induced thrombocytopenia |
| DB00002 | Cetuximab | Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. |
| DB00003 | Dornase alfa | Used as adjunct therapy in the treatment of cystic fibrosis. |
| DB00004 | Denileukin diftitox | For treatment of cutaneous T-cell lymphoma |
| DB00005 | Etanercept | Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis. |
| DB00006 | Bivalirudin | For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned. |
| DB00007 | Leuprolide | For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty |
| DB00008 | Peginterferon alfa-2a | Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label]. |
| DB00009 | Alteplase | For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli |
| DB00010 | Sermorelin | For the treatment of dwarfism, prevention of HIV-induced weight loss |
| DB00011 | Interferon alfa-n1 | For treatment of venereal or genital warts caused by the Human Papiloma Virus |
| DB00012 | Darbepoetin alfa | For the treatment of anemia (from renal transplants or certain HIV treatment) |
| DB00013 | Urokinase | Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots. |
| DB00014 | Goserelin | Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. |
| DB00015 | Reteplase | For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
| DB00016 | Erythropoietin | Indicated in adult and paediatric patients for the:
- treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
- treatment of anemia due to zidovudine in patients with HIV-infection.
- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
- reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery. |
| DB00017 | Salmon Calcitonin | Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause. |
| DB00018 | Interferon alfa-n3 | For the intralesional treatment of refractory or recurring external condylomata acuminata. |
| DB00019 | Pegfilgrastim | Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. |
| DB00020 | Sargramostim | For the treatment of cancer and bone marrow transplant |
| DB00022 | Peginterferon alfa-2b | Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|
| DB00024 | Thyrotropin Alfa | For detection of residueal or recurrent thyroid cancer |
| DB00025 | Antihemophilic factor, human recombinant | For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency. |
| DB00026 | Anakinra | For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). |
| DB00027 | Gramicidin D | For treatment of skin lesions, surface wounds and eye infections. |
| DB00028 | Immune Globulin Human | IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases. |
| DB00029 | Anistreplase | For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
| DB00030 | Insulin Human | Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. |
| DB00031 | Tenecteplase | For treatment of myocardial infarction and lysis of intracoronary emboli |
| DB00032 | Menotropins | For the treatment of female infertility |
| DB00033 | Interferon gamma-1b | Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis. |
| DB00034 | Interferon Alfa-2a, Recombinant | For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection. |
| DB00035 | Desmopressin | - Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).
- Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).
- Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral). |
| DB00036 | Coagulation factor VIIa Recombinant Human | For treatment of hemorrhagic complications in hemophilia A and B |
| DB00038 | Oprelvekin | Increases reduced platelet levels due to chemotherapy |
| DB00039 | Palifermin | For treatment of oral mucositis associated with chemotherapy and radiation therapy. |
| DB00040 | Glucagon recombinant | For treatment of severe hypoglycemia, also used in gastrointestinal imaging |
| DB00041 | Aldesleukin | For treatment of adults with metastatic renal cell carcinoma. |
| DB00042 | Botulinum Toxin Type B | For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. |
| DB00043 | Omalizumab | This drug is an anti-IgE antibody indicated for:
1. Moderate to severe persistent asthma in patients 6 years of age and older
with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids [FDA label]
2. Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment [FDA label] |
| DB00044 | Lutropin alfa | For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L) |
| DB00046 | Insulin Lispro | For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump. |
| DB00047 | Insulin Glargine | For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control. |
| DB00050 | Cetrorelix | For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation |
| DB00051 | Adalimumab | For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. |
| DB00052 | Somatotropin | For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss |
| DB00054 | Abciximab | Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting. |
| DB00055 | Drotrecogin alfa | For reduction of mortality in patients with severe sepsis. |
| DB00056 | Gemtuzumab ozogamicin | Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). |
| DB00057 | Indium In-111 satumomab pendetide | For diagnosis of extrahepatic malignant cancers |
| DB00058 | Alpha-1-proteinase inhibitor | For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. |
| DB00060 | Interferon beta-1a | For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum |
| DB00062 | Human Serum Albumin | Albuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass [F229]. |
| DB00063 | Eptifibatide | For treatment of myocardial infarction and acute coronary syndrome. |
| DB00065 | Infliximab | * Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **Crohn’s disease** who have had an inadequate response to conventional therapy
* Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohn’s disease**.
* Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy.
* Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**.
* Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**.
* Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**.
* Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. |
| DB00066 | Follitropin | In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). |
| DB00067 | Vasopressin | For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding |
| DB00068 | Interferon beta-1b | Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks. |
| DB00069 | Interferon alfacon-1 | For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma |
| DB00070 | Hyaluronidase | For increase of absorption and distribution of other injected drugs and for rehydration. |
| DB00071 | Insulin Pork | For the treatment of type I and II diabetes mellitus. |
| DB00072 | Trastuzumab | For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. |
| DB00073 | Rituximab | For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
| DB00074 | Basiliximab | For prophylactic treatment of kidney transplant rejection |
| DB00075 | Muromonab | For treatment of organ transplant recipients, prevention of organ rejection |
| DB00078 | Ibritumomab tiuxetan | For treatment of non-Hodgkin's lymphoma |
| DB00080 | Daptomycin | For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms. |
| DB00081 | Tositumomab | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) |
| DB00082 | Pegvisomant | Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly. |
| DB00083 | Botulinum Toxin Type A | For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating. |
| DB00086 | Streptokinase | For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae |
| DB00087 | Alemtuzumab | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| DB00089 | Capromab pendetide | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| DB00091 | Cyclosporine | For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis. |
| DB00092 | Alefacept | As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis |
| DB00093 | Felypressin | For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential. |
| DB00094 | Urofollitropin | For treatment of female infertility |
| DB00095 | Efalizumab | For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. |
| DB00098 | Antithymocyte immunoglobulin (rabbit) | For prevention of renal transplant rejection |
| DB00099 | Filgrastim | This drug is a leucocyte growth factor [FDA label] indicated to:
Decrease the incidence of infection‚ as manifested by febrile neutropenia‚
in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [FDA label].
Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia (AML) [FDA label]
Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) [FDA label]
Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [FDA label]
Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [FDA label].
Neupogen is approved for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident [L3739]. |
| DB00102 | Becaplermin | For topical treatment of skin ulcers (from diabetes) |
| DB00103 | Agalsidase beta | For treatment of Fabry's disease (alpha-galactosidase A deficiency) |
| DB00104 | Octreotide | For treatment of acromegaly and reduction of side effects from cancer chemotherapy |
| DB00105 | Interferon Alfa-2b, Recombinant | For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma. |
| DB00106 | Abarelix | For palliative treatment of advanced prostate cancer. |
| DB00107 | Oxytocin | Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability. Oxytocin cannot be used for elective induction of labor, there must be a clear medical requirement. |
| DB00108 | Natalizumab | For treatment of multiple sclerosis. |
| DB00109 | Enfuvirtide | Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. |
| DB00110 | Palivizumab | For prophylaxis of respiratory diseases casued by respiratory syncytial virus. |
| DB00111 | Daclizumab | Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection |
| DB00112 | Bevacizumab | As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. |
| DB00113 | Technetium Tc-99m arcitumomab | For imaging colorectal tumors |
| DB00117 | Histidine | The actions of supplemental L-histidine are entirely unclear. It may have some immunomodulatory as well as antioxidant activity. L-histidine may be indicated for use in some with rheumatoid arthritis. It is not indicated for treatment of anemia or uremia or for lowering serum cholesterol. |
| DB00118 | Ademetionine | S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being. |
| DB00120 | L-Phenylalanine | L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs. |
| DB00123 | L-Lysine | Supplemental L-lysine has putative anti-herpes simplex virus activity. There is preliminary research suggesting that it may have some anti-osteoporotic activity. |
| DB00125 | L-Arginine | Used for nutritional supplementation, also for treating dietary shortage or imbalance. |
| DB00128 | L-Aspartic Acid | There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids. |
| DB00130 | L-Glutamine | Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older [FDA Label]. |
| DB00133 | Serine | Used as a natural moisturizing agent in some cosmetics and skin care products. |
| DB00134 | Methionine | Used for protein synthesis including the formation of SAMe, L-homocysteine, L-cysteine, taurine, and sulfate. |
| DB00135 | L-Tyrosine | Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies. |
| DB00138 | Cystine | It has been claimed that L-cysteine has anti-inflammatory properties, that it can protect against various toxins, and that it might be helpful in osteoarthritis and rheumatoid arthritis. More research will have to be done before L-cysteine can be indicated for any of these conditions. Research to date has mostly been in animal models. |
| DB00142 | Glutamic Acid | Considered to be nature's "Brain food" by improving mental capacities; helps speed the healing of ulcers; gives a "lift" from fatigue; helps control alcoholism, schizophrenia and the craving for sugar. |
| DB00143 | Glutathione | For nutritional supplementation, also for treating dietary shortage or imbalance |
| DB00145 | Glycine | Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities. |
| DB00148 | Creatine | For nutritional supplementation, also for treating dietary shortage or imbalance. |
| DB00149 | L-Leucine | Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress. |
| DB00150 | L-Tryptophan | Tryptophan may be useful in increasing serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight. |
| DB00151 | L-Cysteine | For the prevention of liver damage and kidney damage associated with overdoses of acetaminophen |
| DB00155 | L-Citrulline | Used for nutritional supplementation, also for treating dietary shortage or imbalance. |
| DB00156 | L-Threonine | L-Threonine makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation. |
| DB00160 | L-Alanine | Used for protein synthesis. |
| DB00161 | L-Valine | Promotes mental vigor, muscle coordination, and calm emotions. May also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria. |
| DB00167 | L-Isoleucine | The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity. |
| DB00168 | Aspartame | Used as a diet supplement and sugar substitute. |
| DB00172 | L-Proline | L-Proline is extremely important for the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles. |
| DB00174 | L-Asparagine | Used for nutritional supplementation, also for treating dietary shortage or imbalance. |
| DB00177 | Valsartan | May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors. |
| DB00181 | Baclofen | For the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. |
| DB00183 | Pentagastrin | Used as a diagnostic aid for evaluation of gastric acid secretory function |
| DB00190 | Carbidopa | For treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism |
| DB00230 | Pregabalin | Pregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, and postherpetic neuralgia. It is not approved for the management of fibromyalgia or as adjuntive therapy for adult partial onset seizures.[FDA label] |
| DB00260 | Cycloserine | Used in combination with up to 5 other drugs as a treatment for Mycobacterium avium complex (MAC) and is also used to treat tuberculosis (TB). |
| DB00279 | Liothyronine | Used as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyrodism during the recovery phase of subacute thyroiditis. |
| DB00290 | Bleomycin | For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. |
| DB00314 | Capreomycin | Used in the treatment of tuberculosis in combination with other drugs. |
| DB00362 | Anidulafungin | For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis. |
| DB00403 | Ceruletide | Caerulein stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. As such, it is used in paralytic ileus and as diagnostic aid in pancreatic malfunction. |
| DB00420 | Promazine | Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly. |
| DB00451 | Levothyroxine | For use alone or in combination with antithyroid agents to treat hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor. |
| DB00492 | Fosinopril | For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. |
| DB00509 | Dextrothyroxine | Used to lower high cholesterol levels in the blood. |
| DB00512 | Vancomycin | A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [FDA Label].
Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196]. |
| DB00513 | Aminocaproic Acid | For use in the treatment of excessive postoperative bleeding. |
| DB00520 | Caspofungin | For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies. |
| DB00556 | Perflutren | Used as an ultrasound contrast imaging in cardiology and radiology. |
| DB00577 | Valaciclovir | For the treatment or suppression of cold sores (herpes labialis), herpes zoster (shingles), genital herpes in immunocompetent individuals, and recurrent genital herpes in HIV-infected individuals. |
| DB00584 | Enalapril | For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics. |
| DB00626 | Bacitracin | For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes.
However, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question. |
| DB00642 | Pemetrexed | Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy |
| DB00644 | Gonadorelin | For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation. |
| DB00666 | Nafarelin | For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis. |
| DB00722 | Lisinopril | For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. |
| DB00731 | Nateglinide | For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise. |
| DB00765 | Metyrosine | For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma. |
| DB00775 | Tirofiban | For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| DB00781 | Polymyxin B Sulfate | For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa. |
| DB00803 | Colistin | For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa. |
| DB00837 | Progabide | Indicated for the treatment of epilepsy. |
| DB00855 | Aminolevulinic acid | Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. |
| DB00859 | Penicillamine | For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis. |
| DB00968 | Methyldopa | For use in the treatment of hypertension. |
| DB00970 | Dactinomycin | For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen |
| DB00992 | Methyl aminolevulinate | For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette). |
| DB00996 | Gabapentin | For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. |
| DB01042 | Melphalan | For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone. |
| DB01055 | Mimosine | Not Available |
| DB01072 | Atazanavir | Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. |
| DB01080 | Vigabatrin | For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome. |
| DB01111 | Colistimethate | For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly _Pseudomonas aeruginosa_. |
| DB01141 | Micafungin | For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. |
| DB01197 | Captopril | For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy. |
| DB01221 | Ketamine | Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label]
Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874] |
| DB01229 | Paclitaxel | Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. |
| DB01235 | Levodopa | For the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication. |
| DB01257 | Eculizumab | For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. |
| DB01269 | Panitumumab | For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. |
| DB01270 | Ranibizumab | For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
|
| DB01276 | Exenatide | Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control. |
| DB01277 | Mecasermin | For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. |
| DB01278 | Pramlintide | For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. |
| DB01279 | Galsulfase | For the treatment of adults and children with Mucopolysaccharidosis VI. |
| DB01281 | Abatacept | For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children. |
| DB01282 | Carbetocin | Used to control postpartum hemorrhage and bleeding after giving birth. |
| DB01284 | Tetracosactide | For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. |
| DB01285 | Corticotropin | For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. |
| DB01306 | Insulin Aspart | For the treatment of Type 1 or 2 diabetes mellitus. Should normally be used in conjunction with an intermediate or long-acting insulin. |
| DB01307 | Insulin Detemir | For the treatment of type 1 or 2 diabetes mellitus. May be used in combination with oral anti-diabetic agents in type 2 diabetic patients who are not in adequate metabolic control with oral anti-diabetic agents alone. |
| DB01309 | Insulin Glulisine | For the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents. |
| DB01348 | Spirapril | Spirapril is an ACE inhibitor class drug used to treat hypertension. |
| DB01369 | Quinupristin | For the treatment of bacterial infections (usually in combination with dalfopristin). |
| DB01373 | Calcium | Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades. |
| DB01423 | Stepronin | Strepronin is a mucolytic (expectorant) drug. |
| DB01583 | Liotrix | May be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy. |
| DB01584 | Thyroglobulin | For the treatment of hypothyroidism (deficiency in the production of thyroid hormone). |
| DB01646 | N-Acetylmethionine | Not Available |
| DB01669 | Virginiamycin M1 | For the treatment of bacterial infections. |
| DB01683 | Chymostatin | Not Available |
| DB01686 | N,N-dimethylarginine | Not Available |
| DB01764 | Dalfopristin | For the treatment of bacterial infections (usually in combination with quinupristin). |
| DB01783 | Pantothenic acid | Studied for the treatment of many uses such as treatment of testicular torsion, diabetic ulceration, wound healing, acne, obesity, diabetic peripheral polyneuropathy. It has also been investigated for its hypolipidemic effects and as cholesterol lowering agent. |
| DB01853 | Bacteriochlorophyll A | Not Available |
| DB02011 | N-(Phosphonoacetyl)-L-Ornithine | Not Available |
| DB02083 | N,N-dimethylglycine | Not Available |
| DB02109 | Hadacidin | Not Available |
| DB02123 | Glycochenodeoxycholic Acid | Not Available |
| DB02137 | Molybdenum Cofactor | Not Available |
| DB02174 | D-Glutamine | Not Available |
| DB02216 | S-Methylcysteine | Not Available |
| DB02235 | L-methionine (R)-S-oxide | Not Available |
| DB02236 | Glycinamide Ribonucleotide | Not Available |
| DB02255 | GM6001 | Not Available |
| DB02261 | Platelet Activating Factor | Not Available |
| DB02274 | 7-Keto-8-Aminopelargonic Acid | Not Available |
| DB02307 | N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine | Not Available |
| DB02341 | Mdl 101,146 | Not Available |
| DB02345 | Selenocysteine | Not Available |
| DB02386 | Leucine Phosphonic Acid | Not Available |
| DB02518 | N-Acetylalanine | Not Available |
| DB02543 | Pyrrole-2-Carboxylate | Not Available |
| DB02557 | Phosphoramidon | Not Available |
| DB02578 | Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanyl-D-Alanine | Not Available |
| DB02595 | Bulgecin A | Not Available |
| DB02601 | 4-Hydroxyphenylglycine | Not Available |
| DB02608 | N-Acetyl-P-Nitrophenylserinol | Not Available |
| DB02638 | Terlipressin | Commonly used to stop bleeding of varices in the food pipe (oesophagus). |
| DB02655 | D-Aspartic Acid | Not Available |
| DB02810 | N-(2-Acetamido)Iminodiacetic Acid | Not Available |
| DB02821 | Canaline | Not Available |
| DB02855 | N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline | Not Available |
| DB02952 | Alpha-Aminoisobutyric Acid | Not Available |
| DB02959 | Oxitriptan | For use as an antidepressant, appetite suppressant, and sleep aid. |
| DB02975 | GE-2270A | Not Available |
| DB02978 | Beta-Hydroxyleucine | Not Available |
| DB02999 | Quisqualate | Not Available |
| DB03032 | S-Octylglutathione | Not Available |
| DB03088 | Pidolic Acid | There is currently no clinically approved and/or marketed medicine that relies upon pidolic acid as an active ingredient for any formal therapeutic indication.
Although pidolic acid may be sold in a variety of non-prescription, over-the-counter dietary supplement products for cognitive or memory enhancement, there are many studies that suggest that such products or such supplementation do not elicit any kind of cognitive benefit to users [A32981, A32982]. In fact, the general suggestion for any such pidolic acid product is to exercise caution in their recommendation as much more research is necessary [A32981].
Pidolic acid and sodium pidolic acid are, however, used to some extent in skin and hair conditioning agents owing to their humectant characteristics [F53]. |
| DB03107 | Beta-Alanine | Not Available |
| DB03144 | N-Omega-Hydroxy-L-Arginine | Not Available |
| DB03157 | N,O-Didansyl-L-Tyrosine | Not Available |
| DB03214 | Vinylglycine | Not Available |
| DB03223 | Diphthamide | Not Available |
| DB03251 | RWJ-51084 | Not Available |
| DB03295 | Glutathionylspermidine | Not Available |
| DB03360 | N-Acetylproline | Not Available |
| DB03380 | L-Tyrosinamide | Not Available |
| DB03395 | Enalkiren | Not Available |
| DB03408 | gamma-Glutamylcysteine | Not Available |
| DB03424 | Ubenimex | An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia. |
| DB03425 | 2s,4r-4-Methylglutamate | Not Available |
| DB03436 | Gallichrome | Not Available |
| DB03458 | N(4)-adenosyl-N(4)-methyl-2,4-diaminobutanoic acid | Not Available |
| DB03459 | Sparfosic acid | Not Available |
| DB03470 | Trypanothione | Not Available |
| DB03535 | Z-Pro-Prolinal | Not Available |
| DB03544 | S-Phosphocysteine | Not Available |
| DB03552 | 3-Tyrosine | Not Available |
| DB03632 | Argifin | Not Available |
| DB03640 | Beta-Hydroxyaspartic Acid | Not Available |
| DB03660 | 4-Iodo-L-phenylalanine | Not Available |
| DB03709 | Bicine | Not Available |
| DB03799 | Trifluoromethionine | Not Available |
| DB03817 | 2,4-Diaminobutyric Acid | Not Available |
| DB03880 | Batimastat | Not Available |
| DB03889 | S-(N-Hydroxy-N-Bromophenylcarbamoyl)Glutathione | Not Available |
| DB03940 | Oxamic Acid | Not Available |
| DB04029 | Phenylalanine Amide | Not Available |
| DB04092 | Apstatin | Not Available |
| DB04111 | Balhimycin | Not Available |
| DB04129 | Willardiine | Not Available |
| DB04132 | S-Hexylglutathione | Not Available |
| DB04167 | Aceglutamide | Not Available |
| DB04185 | Norvaline | Not Available |
| DB04189 | N2-(Carboxyethyl)-L-Arginine | Not Available |
| DB04191 | Skf 107457 | Not Available |
| DB04217 | L-2-amino-3-butynoic acid | Not Available |
| DB04223 | Nitroarginine | Not Available |
| DB04269 | Cyclotheonamide A | Not Available |
| DB04284 | L-proline betaine | Not Available |
| DB04291 | Oxfenicine | Not Available |
| DB04308 | D-4-hydroxyphenylglycine | Not Available |
| DB04334 | 6-hydroxydopa quinone | Not Available |
| DB04339 | Carbocisteine | Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis. |
| DB04350 | Argadin | Not Available |
| DB04370 | S-sulphocysteine | Not Available |
| DB04383 | L-Valinol | Not Available |
| DB04391 | Aeruginosin 98-B | Not Available |
| DB04418 | Adenylosuccinic Acid | Not Available |
| DB04436 | 3-Fluorotyrosine | Not Available |
| DB04454 | Alpha-Aminobutyric Acid | Not Available |
| DB04464 | N-Formylmethionine | Not Available |
| DB04495 | RU81843 | Not Available |
| DB04498 | Aspartate Semialdehyde | Not Available |
| DB04527 | Beta-Hydroxyasparagine | Not Available |
| DB04539 | Glyphosate | Not Available |
| DB04584 | Phenyldehydroalanine | Not Available |
| DB04620 | Cycloleucine | Not Available |
| DB04676 | Dansyllysine | Not Available |
| DB04738 | Motuporin | Not Available |
| DB04798 | THIO-ATPA | Not Available |
| DB04805 | Virginiamycin S1 | Not Available |
| DB04847 | Roxadustat | In clinical development for the treatment of anemia of chronic inflammatory disease. |
| DB04869 | Olcegepant | For the treatment of migraine headaches. |
| DB04894 | Vapreotide | For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. |
| DB04897 | Lucinactant | Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. |
| DB04899 | Nesiritide | For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. |
| DB04900 | Thymalfasin | Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization. |
| DB04901 | Galiximab | Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis. |
| DB04911 | Oritavancin | Investigated for use/treatment in bacterial infection and skin infections/disorders. |
| DB04914 | G17DT | Intended for the treatment of various forms of cancer. |
| DB04921 | Dirucotide | For the treatment of multiple sclerosis (MS). |
| DB04925 | Desmoteplase | Investigated for use/treatment in cerebral ischemia and strokes. |
| DB04931 | Afamelanotide | Investigated for use/treatment in actinic keratosis, keratoses, skin cell studies, and skin infections/disorders. |
| DB04949 | Pexelizumab | For the treatment of inflammation during cardiac surgery. |
| DB04952 | Ramoplanin | For the treatment of bacterial infections. |
| DB04956 | Afelimomab | Investigated for use/treatment in sepsis and septicemia. |
| DB04958 | Epratuzumab | Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus. |
| DB04962 | Bectumomab | Investigated for use/treatment in lymphoma (non-hodgkin's). |
| DB04964 | Oregovomab | Investigated for use/treatment in ovarian cancer. |
| DB04972 | Canfosfamide | Intended for the treatment of various forms of cancer. |
| DB04977 | Plitidepsin | Intended for the treatment of various forms of cancer. |
| DB04985 | Tigapotide | For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
|
| DB04988 | IGN311 | Intended for the treatment of various forms of cancer. |
| DB05006 | Adecatumumab | Investigated for use/treatment in breast cancer and prostate cancer. |
| DB05012 | XEN2174 | For the treatment of chronic cancer pain.
|
| DB05029 | Lancovutide | Investigated for use/treatment in cystic fibrosis and eye disorders/infections. |
| DB05032 | REV131 | Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts. |
| DB05034 | Ularitide | Investigated for use/treatment in congestive heart failure. |
| DB05084 | Abaloparatide | Investigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures. |
| DB05092 | CDP323 | Investigated for use/treatment in multiple sclerosis. |
| DB05096 | LY2140023 | Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders. |
| DB05097 | Labetuzumab | Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab" |
| DB05098 | Leptin | Investigated for use/treatment in lipodystrophy and obesity. |
| DB05101 | Matuzumab | Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer. |
| DB05111 | Fontolizumab | Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders. |
| DB05115 | NN344 | Investigated for use/treatment in diabetes mellitus type 1 and 2. |
| DB05128 | Aminocandin | Investigated for use/treatment in fungal infections. |
| DB05130 | INCB3284 | Investigated for use/treatment in inflammatory disorders (unspecified). |
| DB05136 | Bavituximab | Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors. |
| DB05139 | CR002 | Investigated for use/treatment in nephropathy. |
| DB05155 | CR665 | Investigated for use/treatment in pain (acute or chronic). |
| DB05158 | PM02734 | Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors. |
| DB05160 | Topsalysin | Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors. |
| DB05161 | Elafin | Investigated for use/treatment in inflammatory disorders (unspecified). |
| DB05199 | LX1031 | Irritable bowel syndrome (IBS) and other gastrointestinal disorders |
| DB05209 | SYM001 | Investigated for use/treatment in thrombocytopenia. |
| DB05210 | SF1126 | For the treatment of various forms of cancer. |
| DB05258 | Natural alpha interferon | Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma. |
| DB05259 | Glatiramer | For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis. |
| DB05276 | Hepatitis B Immune Globulin | Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications. |
| DB05299 | keyhole limpet hemocyanin | Investigated for use/treatment in bladder cancer and solid tumors. |
| DB05305 | Cintredekin Besudotox | Investigated for use/treatment in brain cancer. |
| DB05311 | Ecallantide | Indicated for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older [FDA Label]. |
| DB05319 | oportuzumab monatox | Investigated for use/treatment in bladder cancer and head and neck cancer. |
| DB05332 | Romiplostim | Treatment of chronic immune thrombocytopenic purpura. |
| DB05336 | Obiltoxaximab | Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. |
| DB05344 | Ciliary neurotrophic factor | Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified). |
| DB05393 | NOV-002 | Investigated for use/treatment in breast cancer, lung cancer, and ovarian cancer. |
| DB05394 | Corticorelin | Investigated for use/treatment in brain cancer and neurologic disorders. |
| DB05396 | Albinterferon Alfa-2B | Investigated for use/treatment in hepatitis (viral, C). |
| DB05405 | XTL-001 | Investigated for use/treatment in hepatitis (viral, B). |
| DB05413 | Tifuvirtide | Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection. |
| DB05434 | ABT-510 | Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors. |
| DB05437 | RIGScan CR49 | Investigated for use/treatment in colorectal cancer and solid tumors. |
| DB05446 | LJP 1082 | Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis. |
| DB05459 | Briakinumab | Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis. |
| DB05460 | Ezatiostat | Investigated for use/treatment in myelodysplastic syndrome. |
| DB05475 | Golotimod | Investigated for use/treatment in hepatitis (viral, C), infectious and parasitic disease (unspecified), and tuberculosis. |
| DB05476 | WX-UK1 | Investigated for use/treatment in solid tumors. |
| DB05496 | Otelixizumab | Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders. |
| DB05507 | VX-765 | Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders. |
| DB05518 | Managlinat dialanetil | Investigated for use/treatment in diabetes mellitus type 2. |
| DB05521 | Telaprevir | Telaprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label]. |
| DB05540 | Alanosine | Investigated for use/treatment in brain cancer and cancer/tumors (unspecified). |
| DB05550 | Iratumumab | Investigated for use/treatment in lymphoma (unspecified). |
| DB05555 | Enokizumab | Investigated for use/treatment in asthma. |
| DB05560 | Delcasertib | Investigated for use/treatment in myocardial infarction. |
| DB05578 | Ramucirumab | For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. |
| DB05595 | Farletuzumab | Investigated for use/treatment in ovarian cancer. |
| DB05599 | Fibroblast growth factor-1 | Investigated for use/treatment in coronary artery disease and peripheral vascular disease. |
| DB05625 | CTCE-9908 | Investigated for use/treatment in cancer/tumors (unspecified), lung cancer, and sarcoma. |
| DB05633 | Glypromate | Investigated for use/treatment in neurologic disorders. |
| DB05645 | Larazotide | Investigated for use/treatment in autoimmune diseases, diabetes mellitus type 1, and gastrointestinal diseases and disorders (miscellaneous). |
| DB05656 | Veltuzumab | Investigated for use/treatment in lymphoma (non-hodgkin's). |
| DB05660 | D-JNKI-1 | Investigated for use/treatment in hearing loss. |
| DB05668 | Palifosfamide | Investigated for use/treatment in cancer/tumors (unspecified), lymphoma (unspecified), and sarcoma. |
| DB05675 | EP-2104R | Investigated for use/treatment in cardiovascular disorders and thrombosis. |
| DB05679 | Ustekinumab | Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease. |
| DB05687 | BL-1020 | Investigated for use/treatment in schizophrenia and schizoaffective disorders. |
| DB05713 | LY-517717 | Investigated for use/treatment in thrombosis and venous thromboembolism. |
| DB05714 | Flovagatran | Investigated for use/treatment in thrombosis. |
| DB05718 | Maxy-G34 | Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. |
| DB05735 | Cefilavancin | Investigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections. |
| DB05739 | CYT006-AngQb | Investigated for use/treatment in hypertension. |
| DB05773 | Trastuzumab emtansine | Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
|
| DB05777 | Thrombomodulin Alfa | Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. |
| DB05779 | Oglufanide | Investigated for use/treatment in hepatitis (viral, C). |
| DB05793 | PRO-542 | Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. |
| DB05797 | TNX-901 | Investigated for use/treatment in allergic reaction. |
| DB05819 | NBI-6024 | Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications. |
| DB05829 | Parathyroid hormone | For use/treatment in osteoporosis. |
| DB05833 | lymphotoxin beta receptor | Investigated for use/treatment in autoimmune diseases. |
| DB05864 | PPI-2458 | Investigated for use/treatment in lymphoma (non-hodgkin's) and solid tumors. |
| DB05875 | substance P | Investigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection. |
| DB05889 | Inotuzumab ozogamicin | Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). |
| DB05892 | RI 624 | Investigated for use/treatment in pain (acute or chronic). |
| DB05915 | MYO-029 | Investigated for use/treatment in muscular dystrophy. |
| DB05931 | Pegdinetanib | Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration. |
| DB05934 | CTCE-0214 | Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases. |
| DB05941 | Leronlimab | Investigated for use/treatment in HIV infection. |
| DB05996 | Glembatumumab vedotin | Investigated for use/treatment in melanoma. |
| DB06043 | Olaratumab | Olaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. |
| DB06049 | IPH 2101 | Investigated for use/treatment in leukemia (myeloid) and multiple myeloma. |
| DB06081 | Caplacizumab | Investigated for use/treatment in cardiovascular disorders and thrombosis. |
| DB06087 | Friulimicin B | Investigated for use/treatment in bacterial infection. |
| DB06101 | IMC-1C11 | Investigated for use/treatment in cancer/tumors (unspecified). |
| DB06116 | Eldelumab | Investigated for use/treatment in ulcerative colitis. |
| DB06138 | IRL-1620 | Investigated for use/treatment in cancer/tumors (unspecified). |
| DB06149 | Teicoplanin | For the treatment of bacterial infections caused by susceptible microorganisms. |
| DB06151 | Acetylcysteine | Acetylcysteine is used mainly as a mucolytic and in the management of paracetamol (acetaminophen) overdose. |
| DB06162 | Lumiliximab | Investigated for use/treatment in asthma and leukemia (lymphoid). |
| DB06168 | Canakinumab | Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). |
| DB06171 | Paclitaxel trevatide | Investigated for use/treatment in brain cancer. |
| DB06176 | Romidepsin | For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. |
| DB06178 | Talotrexin | Investigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid). |
| DB06179 | Darinaparsin | Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer. |
| DB06182 | Talabostat | Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), lung cancer, melanoma, and pancreatic cancer. |
| DB06186 | Ipilimumab | Ipilimumab is approved for different conditions such as:
* Treatment of unresectable or metastatic melanoma in patients 12 years and older.
* Adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.[FDA label]
In combination with [nivolumab], ipilimumab is approved for:
* Treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma
* Treatment of 12 years and older patients with MSI-H/dMMR metastatic colorectal cancer with progression after treatment with fluoropyrimidine, oxaliplatin, and irinotecan.[FDA label] |
| DB06192 | Nimotuzumab | Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer. |
| DB06196 | Icatibant | Approved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections. |
| DB06219 | Dalbavancin | Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, and S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus). It is administered as a 30 minute IV infusion in a two-dose regimen of 1000 mg followed by 500 mg one week later. |
| DB06241 | Clenoliximab | Investigated for use/treatment in rheumatoid arthritis. |
| DB06243 | Eflornithine | Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth). |
| DB06244 | Trafermin | Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers. |
| DB06245 | Lanoteplase | Investigated for use/treatment in myocardial infarction. |
| DB06260 | Aviptadil | Not Available |
| DB06261 | Hexaminolevulinate | Hexaminolevulinate is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. |
| DB06262 | Droxidopa | For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells. |
| DB06273 | Tocilizumab | Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older. |
| DB06285 | Teriparatide | For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. |
| DB06310 | Motavizumab | Investigated for use/treatment in viral infection and pediatric indications. |
| DB06317 | Elotuzumab | Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. |
| DB06323 | AZX-100 | Investigated for use/treatment in scar tissue. |
| DB06335 | Saxagliptin | Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy. |
| DB06342 | Coltuximab ravtansine | Investigated for use/treatment in lymphoma (non-hodgkin's). |
| DB06343 | Teprotumumab | Investigated for use/treatment in solid tumors. |
| DB06360 | Lucatumumab | Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified). |
| DB06366 | Pertuzumab | Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. |
| DB06371 | Siplizumab | Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified). |
| DB06372 | Rilonacept | Rilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout. |
| DB06379 | Calcitonin gene-related peptide | Investigated for use/treatment in myocardial infarction, heart disease, and asthma. |
| DB06399 | Atacicept | Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid). |
| DB06404 | Human C1-esterase inhibitor | For routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). |
| DB06434 | Repifermin | Investigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease. |
| DB06437 | Tifacogin | Investigated for use/treatment in sepsis and septicemia and pneumonia. |
| DB06467 | Apolizumab | Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors. |
| DB06493 | Velafermin | Investigated for use/treatment in adverse effects (chemotherapy). |
| DB06495 | Onercept | Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. |
| DB06508 | GW-559090 | Investigated for use/treatment in asthma and allergic rhinitis. |
| DB06510 | Muraglitazar | Investigated for use/treatment in diabetes mellitus type 2. |
| DB06534 | Thrombopoietin | Investigated for use/treatment in thrombocytopenia. |
| DB06535 | Etilevodopa | Investigated for use/treatment in parkinson's disease. |
| DB06549 | Labradimil | Investigated for use/treatment in brain cancer and pediatric indications. |
| DB06550 | Bivatuzumab | Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer. |
| DB06557 | Lerdelimumab | Investigated for use/treatment in glaucoma and cataracts. |
| DB06562 | Emfilermin | Investigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility. |
| DB06576 | Baminercept | Investigated for use/treatment in rheumatoid arthritis. |
| DB06599 | Lexatumumab | Investigated for use/treatment in cancer/tumors (unspecified). |
| DB06602 | Reslizumab | Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype. |
| DB06606 | Teplizumab | Investigated for use/treatment in diabetes mellitus type 1. |
| DB06607 | Catumaxomab | For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. |
| DB06611 | Pegsunercept | Investigated for use/treatment in rheumatoid arthritis. |
| DB06612 | Mepolizumab | Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history |
| DB06643 | Denosumab | Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. |
| DB06645 | Anamorelin | Investigated for use/treatment in cachexia and anorexia. |
| DB06647 | Volociximab | Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. |
| DB06650 | Ofatumumab | Ofatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. |
| DB06654 | Safinamide | Safinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease |
| DB06655 | Liraglutide | For use in/treatment of diabetes mellitus type 2. |
| DB06657 | Valrocemide | Investigated for use/treatment in epilepsy. |
| DB06663 | Pasireotide | For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option. |
| DB06674 | Golimumab | Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. |
| DB06679 | Amediplase | Investigated for use/treatment in myocardial infarction and thrombosis. |
| DB06681 | Belatacept | For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus. |
| DB06692 | Aprotinin | For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. |
| DB06699 | Degarelix | Degaralix is used for the management of advanced prostate cancer. |
| DB06719 | Buserelin | Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. |
| DB06763 | Saralasin | Not Available |
| DB06775 | Carglumic Acid | For the treatment of acute and chronic hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency. This enzyme is an important component of the urea cycle to prevent build up of neurotoxic ammonium in the blood. |
| DB06785 | Ganirelix | For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. |
| DB06788 | Histrelin | As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer. |
| DB06791 | Lanreotide | Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2) |
| DB06794 | Lodoxamide | Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |
| DB06823 | Tiopronin | Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization. |
| DB06825 | Triptorelin | Triptorelin is indicated for the palliative treatment of advanced prostate cancer. |
| DB06827 | Viomycin | Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis. |
| DB07744 | Z-Val-Ala-Asp fluoromethyl ketone | Not Available |
| DB08508 | N-BENZOYL-D-ALANINE | Not Available |
| DB08626 | Thiorphan | Not Available |
| DB08847 | Hydroxyproline | Used in France as a combination product for the treatment of small, superficial wounds. |
| DB08856 | DADLE | Not Available |
| DB08861 | DPDPE | Not Available |
| DB08862 | Cholecystokinin | For use as a diagnostic aid for evaluation of gallbladder disorders. It is also used in conjunction with secretin in pancreatic insufficiency [L1634]. |
| DB08869 | Tesamorelin | Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. |
| DB08870 | Brentuximab vedotin | Seattle Genetics Announced FDA Approval of ADCETRIS® (Brentuximab Vedotin) in combination with chemotherapy for adults with previously untreated stage III or IV Classical Hodgkin Lymphoma in March 2018 [L1737, L1739].
Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates [FDA label], [L1737].
Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [FDA label]. |
| DB08872 | Gabapentin enacarbil | For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN). |
| DB08873 | Boceprevir | Boceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label]. |
| DB08879 | Belimumab | Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus. |
| DB08885 | Aflibercept | The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin. |
| DB08888 | Ocriplasmin | Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion. |
| DB08889 | Carfilzomib | Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. |
| DB08890 | Linaclotide | Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation. |
| DB08892 | Arbaclofen Placarbil | Investigated for the treatment of spasticity in multiple sclerosis, acute back spasms, and GERD. |
| DB08894 | Peginesatide | Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis |
| DB08900 | Teduglutide | Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. |
| DB08902 | Raxibacumab | Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. |
| DB08904 | Certolizumab pegol | Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). |
| DB08935 | Obinutuzumab | Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. |
| DB08993 | Enviomycin | Not Available |
| DB09029 | Secukinumab | For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy. |
| DB09033 | Vedolizumab | Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. |
| DB09035 | Nivolumab | Nivolumab is indicated as a single agent for the treatment of:
* BRAF V600 wild-type unresectable or metastatic melanoma.
* BRAF V600 mutation-positive unresectable or metastatic melanoma.
* metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on disease-specific FDA therapy.
* advanced renal cell carcinoma with prior anti-angiogenic therapy.
* classical Hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation.
* recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.
* locally advanced or metastatic urothelial carcinoma with disease progression during or after platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
* microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
* hepatocellular carcinoma previously treated with sorafenib.[FDA label]
In combination with [ipilimumab], nivolumab is indicated for the treatment of:
* unresectable or metastatic melanoma.
* melanoma with lymph node involvement or metastatic disease that has gone through complete resection.
* intermediate or poor risk, previously untreated advanced renal cell carcinoma.
* microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.[FDA label] |
| DB09036 | Siltuximab | Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
| DB09037 | Pembrolizumab | Pembrolizumab is indicated for the treatment of:
-Patients with unresectable or metastatic melanoma.[FDA label]
-As a single therapy, pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.[F137]
-As a single therapy, pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to treatment.[F137]
The following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus, the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials.
-Patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS > 1) as determined by an FDA-approved test.[L2955]
-In combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.[F137]
-Patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy.[F137]
-Treatment of adults and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapy.[F137]
-Treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or who have relapsed after 2 or more prior lines of therapy.[F137]
-Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.[F137]
-Patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.[F137]
-Treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.[F137]
-Patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS >1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.[F137] |
| DB09043 | Albiglutide | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| DB09045 | Dulaglutide | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| DB09046 | Metreleptin | Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. |
| DB09052 | Blinatumomab | Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
| DB09059 | Atosiban | Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with:
- regular uterine contractions of at least 30 s duration at a rate of at least 4 per 30 min
- a cervical dilation of 1-3 cm (0-3 for nulliparas) and effacement of at least 50%
- a gestational age from 24-33 completed weeks
- a normal fetal heart rate |
| DB09066 | Corifollitropin alfa | Controlled ovarian stimulation [L2273] in cases of women who are undergoing fertility treatment to stimulate the development of more than one mature egg simultaneously in the ovaries in combination with a gonadotrophin-releasing hormone (GnRH) antagonist (a type of medicine also used in fertility treatments)[L2270]. |
| DB09067 | Corticorelin ovine triflutate | Corticorelin is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. |
| DB09077 | Dinutuximab | Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. |
| DB09098 | Somatrem | Somatrem is a recombinant human growth hormone indicated for: (a) treatment of paediatric patients with growth failure due to growth hormone deficiency (GHD), (b) treatment of paediatric patients with growth failure due to idiopathic short stature (ISS), (c) treatment of paediatric patients with growth failure due to Turner syndrome (TS), (d) treatment of paediatric patients with growth failure due to chronic kidney disease (CKD) up to the time of renal transplantation, (e) treatment of adults with childhood-onset GHD, or (f) treatment of adults with adult-onset GHD [FDA Label]. |
| DB09099 | Somatostatin | For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established. |
| DB09103 | Ancestim | Ancestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.[L1090] The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.[L1089] |
| DB09105 | Asfotase Alfa | Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP). |
| DB09107 | Methoxy polyethylene glycol-epoetin beta | For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required. |
| DB09109 | Turoctocog alfa | Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.[L1105] The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management.[L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.[A31505] |
| DB09122 | Peginterferon beta-1a | For the treatment of patients with relapsing forms of multiple sclerosis. |
| DB09126 | Chorionic Gonadotropin (Human) | For the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for the treatment of selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males and for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins. |
| DB09137 | Technetium Tc-99m mebrofenin | Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent. |
| DB09141 | Protamine sulfate | Protamine sulfate is usually administered to reverse the large dose of heparin administered during certain surgeries, especially heart surgery. |
| DB09142 | Sincalide | As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. |
| DB09164 | Technetium Tc-99m disofenin | Technetium Tc99m Disofenin is indicated as a hepatobiliary imaging agent. Hepatolite is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms. |
| DB09218 | Clonixin | Used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. |
| DB09221 | Polaprezinc | Peptic ulcer disease, dyspepsia [L1308]. |
| DB09222 | Fibrinogen Human | For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. |
| DB09230 | Azelnidipine | For the treatment of hypertension. |
| DB09264 | Idarucizumab | For use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. |
| DB09265 | Lixisenatide | For use as an antihyperglycemic agent in the treatment of T2DM [FDA Label]. |
| DB09272 | Eluxadoline | For the treatment of irritable bowel syndrome with diarrhea (IBS-D). |
| DB09292 | Sacubitril | Used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB. |
| DB09302 | Alirocumab | Alirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease. |
| DB09303 | Evolocumab | For the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering. |
| DB09312 | Antilymphocyte immunoglobulin (horse) | For prevention of renal transplant rejection and for the treatment of aplastic anemia. |
| DB09331 | Daratumumab | For the treatment of patients with multiple myeloma who have received at least three prior lines of therapy (a proteasome inhibitor (PI) and an immunomodulatory agent) or who are double-refractory to a PI and an immunomodulatory agent. This indication was approved by accelerated approval based on response rate. |
| DB09349 | Gastric intrinsic factor | Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to oral iron therapy. |
| DB09357 | Dexpanthenol | Injection: Prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.
Topical: This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy). |
| DB09393 | Amino acids | Not Available |
| DB09421 | Protirelin | Not Available |
| DB09477 | Enalaprilat | Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. |
| DB09527 | Secretin porcine | Not Available |
| DB09559 | Necitumumab | Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC. |
| DB09564 | Insulin Degludec | Insulin degludec is indicated to improve glycemic control in adults with diabetes mellitus. |
| DB09570 | Ixazomib | Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. |
| DB10516 | Casein | Not Available |
| DB10789 | Bordetella pertussis pertactin antigen | Not Available |
| DB11091 | Hydrogen peroxide | Indicated to be used as a disinfectant and sterilizer. |
| DB11095 | Desirudin | Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery. |
| DB11102 | N-acetyltyrosine | N-acetyltyrosine is indicated, in combination with several other amino acids and dextrose, as a peripherally administered source of nitrogen for nutritional support in patients with adequate stores of body fat in whom, for short periods, oral administration cannot be tolerated, is undesirable, or inadequate [FDA Label].
It is also indicated, with other amino acids, 5-10% dextrose, and fat emulsion, for parenteral nutrition to preserve protein and reduce catabolism in stress conditions where oral administration is inadequate [FDA Label].
When administered with other amino acids and concentrated dextrose, it is indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract by the oral, gastrostomy, or jejestomy routes cannot or should not be used or in patients in which gastrointestinal absorption of protein is impaired, metabolic requirements for protein are substantially increased, or morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown [FDA Label] |
| DB11142 | Selenomethionine | Not Available |
| DB11209 | Iron protein succinylate | Not Available |
| DB11210 | Ferrous bisglycinate | Not Available |
| DB11242 | Gelatin | Gelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also used for improving hair condition and to shorten the recovery after exercise and sports-related injury [L2113]. Gelatin is used in preparations of foods, cosmetics, and medicine [L2113].
Plasma volume expander in hypovolaemic shock [L2115]. Haemostatic [L2115].
Gelatin-based hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation. In addition, these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties. Manufacturing technologies such as ultraviolet stereolithography and two-photon polymerization can be used to prepare structures containing photosensitive gelatin-based hydrogels [L2111]. |
| DB11256 | Levomefolic acid | For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272]. |
| DB11296 | Prezatide | Commonly used in cosmetic products for the skin and hair [A19503]. |
| DB11298 | Thioredoxin | Not Available |
| DB11300 | Thrombin | Bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. Additionally, topical bovine thrombin can also be used in combination with an absorbable gelatin sponge, USP [FDA Label]. |
| DB11311 | Prothrombin | For use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. Prothrombin is administered as part of a cocktail containing several coagulation factors. |
| DB11312 | Protein C | Protein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. |
| DB11330 | Factor IX Complex (Human) | Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy. |
| DB11332 | Sinapultide | Infant respiratory distress syndrome [L2502], [L2506], [L2507], [L2511]. |
| DB11364 | Pidotimod | For use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections [L929]. |
| DB11403 | Emodepside | Not Available |
| DB11510 | Deslorelin | Not Available |
| DB11567 | Insulin peglispro | Not Available |
| DB11569 | Ixekizumab | Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| DB11595 | Atezolizumab | For the treatment of patients with locally advanced or metastatic urothelial carcinoma who: 1) have disease progression during or following platinum-containing chemotherapy, and 2) have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. |
| DB11598 | Antithrombin III human | Antithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism |
| DB11611 | Lifitegrast | For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome). |
| DB11621 | Human Varicella-Zoster Immune Globulin | Indicated for preventing and reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals within 4 days of exposure to varicella zoster virus. |
| DB11624 | Epoetin delta | Not Available |
| DB11628 | Depreotide | Not Available |
| DB11631 | Eptotermin Alfa | Not Available |
| DB11639 | Dibotermin alfa | - indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label].
- indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition [L1391]. |
| DB11646 | Conatumumab | Not Available |
| DB11653 | Bremelanotide | Not Available |
| DB11656 | Rebamipide | Not Available |
| DB11657 | Tabalumab | Not Available |
| DB11668 | Rusalatide acetate | Not Available |
| DB11680 | Ficlatuzumab | Not Available |
| DB11682 | Daprodustat | Not Available |
| DB11685 | Figitumumab | Not Available |
| DB11690 | Vonapanitase | Not Available |
| DB11695 | Carnosine | Not Available |
| DB11696 | Racecadotril | Not Available |
| DB11700 | Setmelanotide | Not Available |
| DB11706 | Raxatrigine | Not Available |
| DB11709 | Acetyl hexapeptide-8 | Not Available |
| DB11714 | Durvalumab | Durvalumab is indicated for patients with urothelial carcinoma, such as urinary bladder, urethra or ureter cancer. Patients with prolonged disease progression due to failed platinum-based chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment. Its clinical effectiveness is especially enhanced in PD-L1-positive patient groups [A19123]. |
| DB11715 | Bapineuzumab | Not Available |
| DB11724 | Bombesin | Not Available |
| DB11746 | Onartuzumab | Not Available |
| DB11756 | Solanezumab | Not Available |
| DB11767 | Sarilumab | Indicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate. |
| DB11771 | Tremelimumab | Not Available |
| DB11776 | Brodalumab | Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. |
| DB11777 | Cenderitide | Not Available |
| DB11781 | Tosedostat | Not Available |
| DB11782 | Birinapant | Not Available |
| DB11788 | Neuropeptide Y | Not Available |
| DB11803 | Sirukumab | Not Available |
| DB11808 | Faldaprevir | Not Available |
| DB11815 | Tilarginine | Not Available |
| DB11821 | Danegaptide | Not Available |
| DB11826 | Lampalizumab | Not Available |
| DB11834 | Guselkumab | Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| DB11840 | Dalotuzumab | Not Available |
| DB11842 | Angiotensin II | Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock [FDA Label]. |
| DB11849 | Emibetuzumab | Not Available |
| DB11854 | Astodrimer | Not Available |
| DB11856 | Ligelizumab | Not Available |
| DB11857 | Seribantumab | Not Available |
| DB11862 | Landogrozumab | Not Available |
| DB11865 | Brivanib alaninate | Not Available |
| DB11866 | Romosozumab | Not Available |
| DB11869 | Valspodar | Not Available |
| DB11876 | Alanyl Glutamine | Not Available |
| DB11882 | BPC-157 | Not Available |
| DB11895 | Ghrelin | Not Available |
| DB11906 | Acyline | Not Available |
| DB11915 | Valbenazine | For the treatment of tardive dyskinesia in adults [FDA Label]. |
| DB11928 | Vosoritide | Not Available |
| DB11945 | Avelumab | Indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). |
| DB11955 | Avotermin | Not Available |
| DB11956 | Delanzomib | Not Available |
| DB11958 | Brivanib | Not Available |
| DB11959 | Crenezumab | Not Available |
| DB11972 | Rilotumumab | Not Available |
| DB11975 | TAK-448 | Not Available |
| DB11976 | Anifrolumab | Not Available |
| DB11981 | Elamipretide | Not Available |
| DB11988 | Ocrelizumab | Indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis [FDA Label]. |
| DB11991 | Oprozomib | Not Available |
| DB11997 | Interleukin-7 | Not Available |
| DB12003 | Thymosin beta-4 | Not Available |
| DB12005 | Nirogacestat | Not Available |
| DB12034 | Gantenerumab | Not Available |
| DB12038 | Ulinastatin | Not Available |
| DB12042 | Ibodutant | Not Available |
| DB12044 | MK-0893 | Not Available |
| DB12053 | Visilizumab | Not Available |
| DB12054 | BQ-123 | Not Available |
| DB12056 | Trebananib | Not Available |
| DB12075 | Nagrestipen | Not Available |
| DB12076 | Surotomycin | Not Available |
| DB12088 | TT-232 | Not Available |
| DB12089 | Lorvotuzumab mertansine | Not Available |
| DB12090 | Patritumab | Not Available |
| DB12095 | Telotristat ethyl | As a serotonin synthesis inhibitor, telotristat etiprate, has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome. |
| DB12099 | UK-396,082 | Not Available |
| DB12102 | Fulranumab | Not Available |
| DB12104 | Tarextumab | Not Available |
| DB12105 | Imagabalin | Not Available |
| DB12118 | Sotatercept | Not Available |
| DB12119 | Gevokizumab | Not Available |
| DB12126 | Bradykinin | Not Available |
| DB12132 | Vanutide cridificar | Not Available |
| DB12139 | Alisporivir | Not Available |
| DB12142 | Duligotuzumab | Not Available |
| DB12146 | Rigosertib | Not Available |
| DB12159 | Dupilumab | Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases such as eczema. |
| DB12160 | Bucillamine | Not Available |
| DB12169 | Tralokinumab | Not Available |
| DB12182 | Binetrakin | Not Available |
| DB12189 | Etrolizumab | Not Available |
| DB12205 | Ganitumab | Not Available |
| DB12213 | Etaracizumab | Not Available |
| DB12224 | Oxothiazolidinecarboxylic acid | Not Available |
| DB12240 | Polatuzumab Vedotin | Not Available |
| DB12246 | Inclacumab | Not Available |
| DB12250 | Cixutumumab | Not Available |
| DB12261 | Ascrinvacumab | Not Available |
| DB12271 | ORE-1001 | Not Available |
| DB12274 | Aducanumab | Not Available |
| DB12279 | OBP-801 | Not Available |
| DB12292 | Barusiban | Not Available |
| DB12304 | Entolimod | Not Available |
| DB12330 | Blisibimod | Not Available |
| DB12335 | Tanezumab | Not Available |
| DB12349 | Dulanermin | Not Available |
| DB12363 | Dusigitumab | Not Available |
| DB12370 | Ipamorelin | Not Available |
| DB12373 | Isunakinra | Not Available |
| DB12396 | Fresolimumab | Not Available |
| DB12409 | Vatreptacog alfa | Not Available |
| DB12431 | Muplestim | Not Available |
| DB12444 | Theanine | Not Available |
| DB12451 | SCY-635 | Not Available |
| DB12456 | Bococizumab | Not Available |
| DB12460 | Conbercept | Not Available |
| DB12463 | Semagacestat | Not Available |
| DB12486 | Elobixibat | Not Available |
| DB12489 | Mirvetuximab Soravtansine | Not Available |
| DB12490 | Forigerimod | Not Available |
| DB12493 | PD-217014 | Not Available |
| DB12495 | Selepressin | Not Available |
| DB12498 | Mogamulizumab | For the intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for Sézary Syndrome [FDA label]. |
| DB12514 | Iofolastat I-123 | Not Available |
| DB12519 | Sarcosine | Not Available |
| DB12525 | Molgramostim | Not Available |
| DB12530 | Inebilizumab | Not Available |
| DB12534 | Mavrilimumab | Not Available |
| DB12538 | Nepadutant | Not Available |
| DB12560 | Blosozumab | Not Available |
| DB12566 | Decernotinib | Not Available |
| DB12568 | Tecemotide | Not Available |
| DB12584 | Bimagrumab | Not Available |
| DB12589 | Dacetuzumab | Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma. |
| DB12602 | Pentetreotide | Not Available |
| DB12609 | Tovetumab | Not Available |
| DB12613 | Davunetide | Not Available |
| DB12616 | Sprifermin | Not Available |
| DB12620 | Nerve Growth Factor | Not Available |
| DB12629 | 3,5-diiodothyropropionic acid | Not Available |
| DB12648 | Nona-arginine | Not Available |
| DB12652 | Endothelin-1 | Not Available |
| DB12677 | Soblidotin | Not Available |
| DB12678 | Relamorelin | Not Available |
| DB12684 | Aviscumine | Not Available |
| DB12697 | Methylselenocysteine | Not Available |
| DB12698 | Ibalizumab | Indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in highly treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen [FDA label].
The approval of Trogarzo was supported by a clinical trial of 40 treatment-experienced adults with MDR HIV-1 infection who persistently had elevated levels of HIV RNA in their blood despite heavy antiretroviral therapy. The majority of study patients had previously been treated with ≥10 antiretroviral medications [L1554]. |
| DB12699 | Balugrastim | Not Available |
| DB12701 | Intetumumab | Not Available |
| DB12711 | LTX-109 | Not Available |
| DB12718 | Carlumab | Not Available |
| DB12726 | Monteplase | Not Available |
| DB12730 | Dolastatin 10 | Not Available |
| DB12732 | Firategrast | Not Available |
| DB12734 | Demcizumab | Not Available |
| DB12738 | Tiplimotide | Not Available |
| DB12748 | LTX-315 | Not Available |
| DB12750 | N-omega-nitro-L-arginine methyl ester | Not Available |
| DB12755 | Zoptarelin doxorubicin | Not Available |
| DB12762 | Rabacfosadine | Not Available |
| DB12775 | Abituzumab | Not Available |
| DB12777 | Somatoprim | Not Available |
| DB12795 | CMX-2043 | Not Available |
| DB12807 | Naptumomab Estafenatox | Not Available |
| DB12815 | Crotedumab | Not Available |
| DB12820 | Concizumab | Not Available |
| DB12822 | Pancreatic Polypeptide | Not Available |
| DB12826 | Depatuxizumab | Not Available |
| DB12827 | Indoximod | Not Available |
| DB12835 | Olipudase alfa | Not Available |
| DB12844 | Rontalizumab | Not Available |
| DB12845 | Amatuximab | Not Available |
| DB12849 | Clazakizumab | Not Available |
| DB12863 | Sivelestat | Not Available |
| DB12865 | Etelcalcetide | Etelcalcetide is a calcium-sensing receptor agonist indicated for:
Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. |
| DB12870 | Buthionine Sulfoximine | Not Available |
| DB12876 | GS-9256 | Not Available |
| DB12878 | AV-101 | Not Available |
| DB12880 | Interleukin-10 | Not Available |
| DB12882 | Ombrabulin | Not Available |
| DB12891 | Ozanezumab | Not Available |
| DB12893 | Sacituzumab govitecan | Not Available |
| DB12909 | Factor XIII (human) | Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. |
| DB12938 | Isoxaflutole | Not Available |
| DB12943 | Milatuzumab | Not Available |
| DB12951 | Pivagabine | Not Available |
| DB12976 | Robatumumab | Not Available |
| DB12992 | Bleomycin A6 | Not Available |
| DB13006 | Cibinetide | Not Available |
| DB13033 | Urocortin-2 | Not Available |
| DB13045 | Racotumomab | Not Available |
| DB13067 | Rotigaptide | Not Available |
| DB13068 | 9-(N-methyl-L-isoleucine)-cyclosporin A | Not Available |
| DB13074 | Macimorelin | Indicated for the diagnosis of adult growth hormone deficiency (AGHD) [FDA Label]. |
| DB13091 | Tiropramide | Not Available |
| DB13127 | Olokizumab | Not Available |
| DB13133 | Von Willebrand Factor Human | The vWF and Factor VIII complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand disease patients. It is also indicated for the on-demand treatment and control of bleeding episodes.[L1880] The von Willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von Willebrand factor (vWF). Due to this deficiency, the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding. There are three types of this disease, and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vWF.[L1867] |
| DB13144 | Lenograstim | The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion.
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome). |
| DB13146 | Fluciclovine (18F) | Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.[A31388] The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.[A31389] |
| DB13148 | Coagulation factor X human | Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label]. |
| DB13149 | Protein S human | For use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors. |
| DB13150 | Coagulation factor VII human | May be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures. |
| DB13166 | Zofenopril | Not Available |
| DB13191 | Phosphocreatine | Phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates. Its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate (ATP) for muscular activity like contractions.
Given this utility of phosphocreatine to recycle ATP, the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements - such as in ischemic stroke and other cerebrovascular diseases. It is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications, although it is administered intravenously for cardiovascular conditions in some countries.
Additionally, because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics. |
| DB13192 | Antihemophilic factor human | The human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes.[L1055] If surgery is needed in patients with hemophilia A there is a need of correction of the clotting abnormality. In this cases, the human antihemophilic factor may be administered followed by intermittent maintenance doses.[L1053] The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding.[T56] |
| DB13200 | Lipegfilgrastim | Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441]. |
| DB13201 | Trenonacog alfa | Not Available |
| DB13207 | Arginine glutamate | Not Available |
| DB13226 | Acetylleucine | Not Available |
| DB13233 | Alaproclate | Not Available |
| DB13257 | Ferrous sulfate anhydrous | For the prevention and treatment of iron deficiency anemia [L2252].
|
| DB13359 | Magnesium aspartate | Not Available |
| DB13375 | Edrecolomab | Not Available |
| DB13503 | Tyrothricin | Tyrothricin is used as an over the counter topical antibiotic. |
| DB13615 | Mifamurtide | Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy [L1203]. |
| DB13626 | Aluminium glycinate | Not Available |
| DB13646 | Saruplase | Not Available |
| DB13704 | Pristinamycin | Not Available |
| DB13809 | Paclitaxel poliglumex | Not Available |
| DB13864 | Hemoglobin crosfumaril | Not Available |
| DB13886 | Human cytomegalovirus immune globulin | It is used to prevent cytomegalovirus (CMV) disease after organ transplant [L2225].
Cytomegalovirus Immune Globulin Intravenous (Human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart [FDA label].
In transplants of these organs other than the kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir [FDA label]. |
| DB13923 | Emicizumab | The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A with or without Factor VIII inhibitors.[L4657]
Hemophilia A is a deficiency of coagulation Factor VIII which causes a serious bleeding disorder. The standard treatment is done with the administration of recombinant or serum-deriver Factor VIII which induces the formation of anti-factor VIII alloantibodies (Factor VIII inhibitors) and renders the standard treatment ineffective.[A31286] |
| DB13928 | Semaglutide | Semaglutide is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct of diet and exercise. The approved therapeutic doses are 0.5 mg and 1 mg.[L1068] Diabetes mellitus type 2 is a long-term metabolic disorder characterized by high blood sugar, insulin resistance and lack of insulin. Its onset is determined by the loss ability of beta cells to respond to an increased plasma glucose. This disease is predominantly caused by lifestyle factors like overweight and obesity. The key feature on type 2 diabetes is the presence of insulin resistance which reduced the capacity of insulin to exert its functions at normal at any given concentration. The secretion of insulin is stimulated by the action of incretins in the gut like glucagon-like peptide 1, which also delays gastric emptying and induces satiety, and glucose-dependent insulinotropic polypeptide.[T59] |
| DB13931 | Netarsudil | Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [FDA Label]. |
| DB13933 | Nonacog beta pegol | Nonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56] |
| DB13968 | Plasma protein fraction (human) | PPFh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy. It is also used as a substitution therapy in emergency cases of factor deficiencies, for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy. PPFh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpura.[L2264]
PPFh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cells.[L2261] |
| DB13972 | Racemethionine | Not Available |
| DB13976 | Sulesomab | Not Available |
| DB13979 | Besilesomab | Besilesomab is radiolabelled with sodium pertechnetate (Tc99m) solution to develop technetium (Tc99m) besilesomab solution. This solution is indicated in adults for scintigraphic imaging - in conjunction with other appropriate imaging modalities, when possible - in determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. When utilized as such, this medicinal product is for diagnostic use only [FDA Label]. |
| DB13985 | Lutetium Lu 177 dotatate | Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults [FDA Label]. |
| DB13999 | Moroctocog alfa | Moroctocog Alfa is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
Moroctocog Alfa is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency). |
| DB14004 | Tildrakizumab | Moderate-severe plaque psoriasis [L1858], [FDA label]. |
| DB14027 | Taspoglutide | Not Available |
| DB14028 | Nordazepam | Not Available |
| DB14039 | Erenumab | Erenumab is indicated for the preventative treatment of migraine in adults [FDA Label]. |
| DB14041 | Fremanezumab | The ongoing trials for fremanezumab are for episodic and chronic migraine prevention and also for cluster headache [A33114]. |
| DB14044 | Hopantenic acid | Not Available |
| DB05624 | Teverelix | Investigated for use/treatment in benign prostatic hyperplasia, endometriosis, and prostate cancer. |
| DB14057 | Valinomycin | Not Available |
| DB14058 | Basifungin | Not Available |
| DB14072 | Reversin 121 | Not Available |
| DB14103 | Methionine sulfoximine | Not Available |
| DB14127 | Sacubitrilat | Not Available |
| DB14131 | Basic Fibroblast Growth Factor | Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications. |
| DB14145 | Nepidermin | Not Available |
| DB14207 | Fosinoprilat | Not Available |
| DB14211 | Fanolesomab | Not Available |
| DB14218 | Telotristat | Not Available |
| DB14472 | Insulin-like growth factor II | Not Available |
| DB14473 | Beroctocog alfa | Not Available |
| DB14479 | Acetylcysteine zinc | Not Available |
| DB14480 | Acetylcysteine amide | Not Available |
| DB14493 | Zinc glycinate | Not Available |
| DB09532 | Secretin human | Indicated for the stimulation of:
- pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction [FDA Label].
- gastrin secretion to aid in the diagnosis of gastrinoma [FDA Label].
- pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) [FDA Label]. |
| DB14562 | Andexanet alfa | Andexanet alfa is indicated for patients treated with [rivaroxaban] and [apixaban], when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding [L3725]. Andexxa has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban and rivaroxaban [L3725]. |
| DB14597 | Lanadelumab | Lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedema.[L4537]
The hereditary angioedema (HEA) is an autosomal dominant disorder resulted from the presence of C1 deficiency. Some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited. This condition is manifested by attacks of subcutaneous or submucosal edema in the face, larynx, GI tract, limbs or genitalia. From all the types of attacks, the most serious is the laryngeal as it can compromise the airway. The rest of the attacks are accompanied by pain and considerable dysfunction.[A38679] |
| DB09329 | Antihemophilic Factor (Recombinant), PEGylated | For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064].
This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label]. |
| DB14642 | Lypressin | Not Available |
| DB14683 | Prezatide copper | Commonly used in cosmetic products for the skin and hair [A19503]. |
| DB12688 | Moxetumomab Pasudotox | MxP is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies including treatment with a purine nucleoside analog. The use of this drug is not recommended in patients with severe renal impairment (CrCl < 29 ml/min).[L4568]
HCL is an uncommon type of lymphocytic leukemia that starts in B cells or B lymphocytes. It is characterized by an accumulation of abnormal B lymphocytes. HCL is called "hairy" as it produces hair-like projections in the surface of the cancer cells. A usual symptom in people having HCL is the presence of splenomegaly and less often hepatomegaly.[A38877] |
| DB08766 | Zofenoprilat | Not Available |
| DB06111 | AB192 | Investigated for use/treatment in diabetes mellitus type 2. |
| DB14042 | Galcanezumab | Galcanezumab is a humanized monoclonal antibody that is indicated for migraine prophylaxis in adults by binding endogenous human calcitonin gene-related peptide (CGRP) [A33112, FDA Label]. |
| DB07558 | acetylleucyl-leucyl-norleucinal | Not Available |